Skip to main content
. 2022 Feb 11;21(4):568–581. doi: 10.1158/1535-7163.MCT-21-0518

Figure 2.

Figure 2. PhAc-ALGP-Dox is highly potent and selective toward in vitro cancer models. A–E, Dose–response curves after 72 hours' exposure to Dox (blue) or PhAc-ALGP-Dox (purple) in 2D monolayers for (A) murine TNBC (E0771), (B) normal murine epithelium (HC-11), (C) human TNBC (MDA-MB-231 and MDA-MB-468), (D) human CrC (LS 174T), or (E) normal human epithelium (HME-1). Graphs are presented as sigmoidal nonlinear fittings, normalized to nontreated controls. F–H, Growth of MDA-MB-231 spheroids after exposure to different concentrations of (F) Dox or (G) PhAc-ALGP-Dox. H, Representative bright field images of spheroids at day 17. I–K, Growth of LS 174T spheroids treated with (I) Dox or (J) PhAc-ALGP-Dox. K, Representative bright field images of LS 174T spheroids at day 14. Data are represented as mean ± SEM of three to five experiments, run in triplicate (n = 9–15). ##, P < 0.01 and ****, P < 0.0001 versus. controls as defined by two-way ANOVA. Scale bar, 200 μm. CrC, colorectal carcinoma; NT, nontreated; TNBC, triple-negative breast cancer.

PhAc-ALGP-Dox is highly potent and selective toward in vitro cancer models. A–E, Dose–response curves after 72 hours' exposure to Dox (blue) or PhAc-ALGP-Dox (purple) in 2D monolayers for (A) murine TNBC (E0771), (B) normal murine epithelium (HC-11), (C) human TNBC (MDA-MB-231 and MDA-MB-468), (D) human CrC (LS 174T), or (E) normal human epithelium (HME-1). Graphs are presented as sigmoidal nonlinear fittings, normalized to nontreated controls. F–H, Growth of MDA-MB-231 spheroids after exposure to different concentrations of (F) Dox or (G) PhAc-ALGP-Dox. H, Representative bright field images of spheroids at day 17. I–K, Growth of LS 174T spheroids treated with (I) Dox or (J) PhAc-ALGP-Dox. K, Representative bright field images of LS 174T spheroids at day 14. Data are represented as mean ± SEM of three to five experiments, run in triplicate (n = 9–15). ##, P < 0.01 and ****, P < 0.0001 versus. controls as defined by two-way ANOVA. Scale bar, 200 μm. CrC, colorectal carcinoma; NT, nontreated; TNBC, triple-negative breast cancer.